Egis, the Group’s generic drugs subsidiary in Central and Eastern Europe, inaugurated a new production unit and a brand new packaging plant at its Körmend site (in the west of Hungary) on October 15, in the presence of Dr. István Hodász, CEO of Egis, Béatrice Bihr, Executive Vice President General Secretariat at Servier and Péter Szijjártó, the Minister of Foreign Affairs and Trade of Hungary.
In the newly established production plant, Egis has installed state-of-the-art and innovative equipment, specially adapted to the development and manufacturing of anti-cancer drugs. Thanks to this new investment, the Servier subsidiary is now able to implement all value creation processes in the field of oncology, from development to the manufacture of the active ingredient and the finished drug.
“With our new investment, all steps of the development and manufacturing of oncology products can be implemented at Egis. Thus, we can contribute to the treatment of oncology patients with up-to-date generic products that are, regarding all processes, fully controlled and reliable, domestically developed and manufactured” – said Dr. István Hodász, CEO of Egis Pharmaceuticals PLC.
To establish a new packaging facility was a timely move in order to relieve congestion in the old packaging plant. The infrastructure can be expanded in the future and will allow Egis to respond flexibly to the growing demands of the market. The highly competitive Hungarian pharmaceutical industry recorded the fourth highest growth rate in 2020 and increased its performance by 4% between January and August 2021 (1).
At a glance
(1) Source: Hungarian Central Statistical Office (KSH)